TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.
Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, Vairo G, Fuller K, Erber WN, Sadras T, Grose R, Yeung DT, Lopez AF, Hiwase DK, Hughes TP, White DL.
Nievergall E, et al. Among authors: kok ch.
Leukemia. 2016 Jun;30(6):1263-72. doi: 10.1038/leu.2016.34. Epub 2016 Feb 22.
Leukemia. 2016.
PMID: 26898188
Clinical Trial.